ADHD stimulant treatment could decrease female substance abuse risk, study suggests
07 Oct 2008

Therapy with stimulant drugs appears to significantly decrease the chance of girls with attention deficithyperactivity disorder (ADHD) starting to smoke, use alcohol or take drugs, a study has suggested.

Carried out by researchers at US institution Massachusetts General Hospital, the study is published in the October edition of Archives of Pediatrics and Adolescent Medicine.

The staff analysed data from 114 participants between the ages of six and 18 and used standardised assessments for use, abuse and dependence of alcohol, tobacco, cannabis and other drugs five years after the study began.

"Comparing results from the 94 participants who received stimulant treatment with the 20 who had not been treated indicated that treatment cut in half the risk of smoking, drinking alcohol or drug abuse," the study stated.

Dr Timothy Wilens, leader of the study, said the staff suspect treatment "at least" delays the onset of smoking and substance abuse in girls with ADHD.

Login and visit the ADHD Knowledge Centre

Print Article    Bookmark

• Study dismisses sugar as encouraging hyperactivity 18/12/08
• ADHD symptoms may affect ability to quit smoking, study suggests 24/11/08
• ADHD drugs' genetic damage fears allayed in new study 21/11/08
• Movement study shows difference in sexes for ADHD sufferers 04/11/08
• ADHD and serious nicotine addiction risk 24/10/08

• CONCERTA XL Prolonged-release Tablets - 49.42%
  CONCERTA® XL is indicated as part of a comprehensive treatment programme for Attention Deficit Hyperactivity Disorder (ADHD) in children (over 6 years of age) and adolescents when remedial measures alone prove insufficient. Diagnosis must be made according to DSM-IV criteria or the guidelines in ICD ...
  
  
• EQUASYM Tablets - 47.03%
  Methylphenidate is indicated as part of a comprehensive treatment programme for attention-deficit hyperactivity disorder (ADHD) in children over 6 years of agewhen remedial measures alone prove insufficient. The decision to treat as well as follow-up must be under supervision of a specialist in ...
  
  
• EQUASYM XL Capsules - 46.1%
  Equasym XL is indicated as part of a comprehensive treatment programme for attention-deficit/hyperactivity disorder (ADHD) in children over 6 years of age when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders ...
  
  
• STRATTERA - 46.1%
  Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older and in adolescents as part of a comprehensive treatment programme. Diagnosis should be made according to DSM-IV criteria or the guidelines in ICD-10. Additional information ...
  
  
• RITALIN - 46.1%
  Indicated for the treatment of Attention-deficit Hyperactivity Disorder. (ADHD ...
  
  
• DEXEDRINE - 46.1%
  Narcolepsy; refractory hyperkinetic states in children under specialist supervision. (ADHD ...